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Abstract
Purpose To evaluate the safety and efficacy of radiofrequency (RF) ablation of the basivertebral nerve (BVN) for the treat-
ment of chronic low back pain (CLBP) in a Food and Drug Administration approved Investigational Device Exemption trial. 
The BVN has been shown to innervate endplate nociceptors which are thought to be a source of CLBP.
Methods A total of 225 patients diagnosed with CLBP were randomized to either a sham (78 patients) or treatment (147 
patients) intervention. The mean age within the study was 47 years (range 25–69) and the mean baseline ODI was 42. All 
patients had Type I or Type II Modic changes of the treated vertebral bodies. Patients were evaluated preoperatively, and at 
2 weeks, 6 weeks and 3, 6 and 12 months postoperatively. The primary endpoint was the comparative change in ODI from 
baseline to 3 months.
Results At 3 months, the average ODI in the treatment arm decreased 20.5 points, as compared to a 15.2 point decrease in 
the sham arm (p = 0.019, per-protocol population). A responder analysis based on ODI decrease ≥ 10 points showed that 
75.6% of patients in the treatment arm as compared to 55.3% in the sham control arm exhibited a clinically meaningful 
improvement at 3 months.
Conclusion Patients treated with RF ablation of the BVN for CLBP exhibited significantly greater improvement in ODI at 
3 months and a higher responder rate than sham treated controls. BVN ablation represents a potential minimally invasive 
treatment for the relief of chronic low back pain.
Graphical abstract These slides can be retrieved under Electronic Supplementary Material.
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1. The basivertebral nerve complex innervates VB endplates
2. Hypothesized that ablating the BVN would aleviate chronic low back pain
3. A randomized, blinded clinical trial showed that RF ablation of the BVN 
was more effective at improving function and reducing pain than a sham
[Citation]
Take Home Messages
1. Mechanical back pain arising from DDD is transmitted through the BVN
2. Patients treated with percutaneous, transpedicular, RF ablation of the BVN 
reported about one grade decrease in ODI and substantial improvement in 
VAS
3. The Intracept procedure represents a new, minimally invasive method of 
providing relief of chronic low back pain
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Introduction
Low back pain (LBP) is the most common cause of activ-
ity limitation in individuals younger than 45 years of age. 
While conservative and invasive treatments may be used 
to treat CLBP, both may prove to be only moderately effec-
tive and/or of temporary duration. For example, Fritzell 
et al. found an 11 point decrease in ODI in patients fused 
for CLBP, but also noted that the improvement in pain 
gradually deteriorated after 6 months [1]. Brox et al. sug-
gested that the success rate of fusion was little better than 
cognitive intervention [2]. Although several authors have 
shown good improvement in outcome measures following 
total disc replacement and/or lumbar fusion [3, 4], both are 
invasive surgical interventions with prolonged recovery 
periods [5].
Chronic low back pain has been associated with disc 
degeneration and discogenic pain, attributed to pain signals 
arising from nerves in the posterior annulus. In addition, the 
existence and role of nerves within bone as well as within 
the disc is documented. For example, Sherman described 
the rich nerve supply in human bones, including within the 
vertebral body, and noted that these nerves mostly appeared 
to be non-myelinated [6].
Crock and Yoshizawa mapped the vertebral body vessels 
and reported that the nerves were collocated with the vessels 
[7]. In 1997, Brown et al. studied the cartilage endplates and 
underlying cancellous bone obtained from patients operated 
for degenerative disc disease (DDD) presenting with and 
without chronic back pain. In patients with severe back pain, 
they observed proliferation of blood vessels at the disc–end-
plate interface, which they identified as sensory nerves using 
immunohistochemical techniques including immunoreactiv-
ity to substance P. They noted that the increased density of 
nociceptors in conjunction with endplate cartilage defects 
strongly suggested that the endplates and vertebral bodies 
were the sources of pain in patients with DDD [8].
Specific mapping of human vertebral body nerves was 
performed by Antonacci et al. who examined 69 vertebral 
bodies and found that nerves entered the vertebral body pos-
teriorly via the basivertebral foramen. These basivertebral 
nerves, which branch from the sinuvertebral nerve, followed 
the course of the nutrient arteries, clustering at the vertebral 
center, then branching to the endplates. They postulated that 
these nerves could play a role in low back pain [9]. Similarly, 
Bailey et al. used PGP 9.5 staining to describe the morphol-
ogy of the BVN including its vertebral body entry through 
posterior foramina [10]. Confirmatory evidence that the 
BVN complex transmits nociceptive signals was made by 
Fras et al. who observed the basivertebral nerves stained for 
the presence of substance P [11].
While sensitized nociceptors within the posterior annulus 
of degenerating discs have been identified as a source or 
origin for so called “discogenic” low back pain, the pres-
ence, anatomic course and nociceptive capacity of the BVN 
suggests an additional hypothesis: that in some patients the 
origin of low back pain is the vertebral endplates, and that 
pain is transmitted through signals emanating in the BVN 
complex. This hypothesis is buttressed by the observation 
that the density of endplate and vertebral body innervation 
via the basivertebral nerve is higher than that of the annu-
lus, suggesting that some CLBP traditionally reported as 
discogenic in origin is in fact vertebrogenic [12]. Clinical 
evidence into the role of the BVN in the transmission of 
pain in patients with CLBP was provided by Becker et al. 
They used unilateral transpedicular access and RF energy 
to ablate the BVN in a series of 16 patients presenting with 
axial back pain, who were subsequently followed for 1 year. 
In their series, they observed an improvement in ODI from 
52 ± 13 at baseline to 23 ± 21 at 3 months (p < 0.001); the 
improvement was maintained out to 1 year [13].
We report on a double-blind, randomized, clinical trial 
designed to further test the hypothesis that interrupting pain 
transmission from the BVN could alleviate CLBP in patients 
with Modic type 1 or 2 abnormalities of the endplates.
Methods
Study design
Between October 2011 and February 2014, 225 patients 
were randomized to a prospective, multi-center, double-
blind, sham-controlled, FDA approved Investigational 
Device Exemption clinical trial (registered with Clinical-
Trials.gov as NCT01446419) at 15 investigational sites in 
the United States and three sites in Germany. The primary 
objective was to evaluate the safety and efficacy of using RF 
energy to ablate the BVN for the treatment of chronic axial 
low back pain.
The primary inclusion criteria included skeletally mature 
patients with chronic (≥ 6 months), isolated lumbar pain, 
who had not responded to at least 6 months of non-operative 
management. Type 1 or Type 2 Modic changes were required 
at the proposed treatment levels and treatment was limited 
to a minimum of two and a maximum of three consecutive 
vertebral body levels from L3–S1. In addition, candidate 
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patients had to report a minimum ODI of 30 points (100 
point scale) and a minimum VAS of 4 cm (10 cm scale).
Exclusion criteria included radicular pain, previous lum-
bar spine surgery, symptomatic spinal stenosis, diagnosed 
osteoporosis (T < 2.5), disc extrusion or protrusion > 5 mm, 
spondylolisthesis > 2 mm at any level, 3 or more Waddell’s 
signs of Inorganic Behavior, and a Beck Depression Inven-
tory of greater than 24. Radicular pain was considered to be 
any pain that traveled along a dermatomal distribution into 
the lower extremity, causing pain, numbness, and/or weak-
ness/heaviness of the affected area. Symptomatic spinal ste-
nosis was defined as the presence of neurogenic claudication 
as confirmed by imaging, with symptoms typically including 
a combination of discomfort, pain, numbness, and weakness 
in the calves, buttocks, and/or thighs, often brought on by 
walking or prolonged standing, but relieved by flexion or 
sitting. In addition, patients involved in litigation related to 
back pain or injury, patients receiving disability compensa-
tion, and patients prescribed extended release narcotics were 
not eligible.
Final selection of study patients was arbitrated by a panel 
of three spine surgeons of which two had to agree on the 
proposed patient’s medical, clinical, and radiographic pres-
entation prior to inclusion in the study.
Once a patient was enrolled, pre-operative mapping was 
performed at each candidate vertebral body to determine the 
relative location of the branch point or terminus of the BVN, 
typically between 40 and 60% of the posterior to anterior 
distance across the vertebral body. An example showing the 
determination of the relative position of the BVN terminus 
is shown in Fig. 1.
Patients were randomized using 2:1 block randomiza-
tion to either the treatment or the sham arm. Randomization 
occurred at each investigational site in random blocks of six 
or nine patients and arm determination was made after the 
patient was under anesthesia. Anesthetic choice was a func-
tion of patient/physician practices and preferences; 113 of 
225 (50.2%) of patients in the study received general anes-
thesia and 112 of 225 (49.8%) of patients received moderate 
conscious sedation.
The treatment arm patients received thermal ablation at 
the terminus of the BVN using a transpedicular delivery 
system  (Intracept® System, Relievant Medsystems, Red-
wood City, CA, USA). This system consisted of a set of 
access instruments, straight and curved cannulae, a bipolar 
RF probe to deliver thermal energy, and an RF generator.
The procedure is performed unilaterally with the patient 
in a prone position; either general or conscious sedation 
is administered. Using standard anatomic landmarks, the 
location of the entry pedicle at each level to be treated is 
determined and marked. Under fluoroscopic guidance, an 
introducer cannula is advanced through the pedicle until 
the trocar just breaches the posterior vertebral wall. The 
introducer trocar is exchanged with a smaller plastic can-
nula/curved nitinol stylet assembly, which facilitates the 
creation of a curved path from the posterior wall to the 
pre-determined target located at the terminus of the BVN, 
located near the center of the vertebral body. Finally, the 
curved nitinol stylet is removed and an RF probe is intro-
duced positioned at the terminus of the BVN. The bipolar 
RF probe is activated and the temperature at the tip is 
maintained at a constant 85 °C for 15 min, a tempera-
ture and time determined in bovine pre-clinical models to 
create an approximately 1 cm spherical lesion within the 
vertebral body.
Patients in the sham arm underwent the same operating 
room protocol for the same overall duration as the treat-
ment arm patients. However, the sham surgical procedure 
consisted only of docking the introducer cannula 1–2 mm 
into the pedicle and simulating the RF ablation, including 
an equivalent dwell time. To maintain blinding, the treat-
ing and follow-up physicians differed. At 1 year, patients 
in the sham arm were permitted to cross-over to the active 
treatment.
Fig. 1  Targeting of the ablation is performed preoperatively on a 
sagittal or coronal (not shown) image of the level to be treated. The 
distance from the posterior wall to the end of the channel with the 
basivertebral vessels (A) is measured and divided by the overall 
posterior-to-anterior dimension of the vertebral body (B). The ratio 
A/B is noted and the RF probe is guided to the same relative position 
under fluoroscopic guidance during the treatment procedure
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Clinical and radiographic outcome measurements
Outcomes were evaluated using the Oswestry Disability Index 
questionnaire (ODI) and the Medical Outcomes Trust Short-
Form Health Survey (SF-36). Back pain was assessed using a 
visual analog scale (VAS) on a 10-cm scale ranging from 0 (no 
pain) to 10 (worst imaginable pain). Physical and neurologi-
cal examinations were performed at each interval, while MR 
imaging was performed at 6 weeks and 6 months. MR imaging 
(T1, T2, and STIR time constants) was obtained at the 6-week 
and 6-month follow-up visits. Radiographic assessments were 
performed by a blinded independent radiologist. Patients were 
assessed for changes in Modic Type presentation at L3 through 
S1 at 6-week and 6-month follow-up.
Statistical and data evaluation methods
Sample size was calculated assuming mean ODI would 
exhibit a standard deviation of 20 points and the study was 
powered to detect a 10 point between-group difference in 
ODI with 90% power and α = 0.05. These assumptions 
yielded a sample size of 133 treatment and 67 sham patients.
The primary efficacy endpoint was the 3 month change 
in ODI. Descriptive statistics evaluated the change using 
an analysis of covariance, with the covariates consisting of 
treatment group, analysis center, treatment group by analysis 
center interaction, and the baseline ODI score. The SF-36 
and VAS metrics were analyzed similarly.
Two pre-planned analysis groups were defined within 
the FDA approved IDE protocol which governed the study. 
These were the intent-to-treat (ITT) and the per-protocol 
(PP) populations. The ITT population consisted of the 
patients as randomized. However, because the study was ran-
domized to a surgical procedure, the possibility of an unsuc-
cessful procedure was admitted, with the most likely cause 
being failure of the RF generated lesion to be collocated 
with the terminus of the BVN. The per-protocol population 
excluded such patients as well as any patients in which the 
procedure could not be carried out, or who were not compli-
ant with the post-operative protocol.
The safety endpoints consisted of the incidence and sever-
ity of adverse events and serious adverse events, both pro-
cedure and device related, the maintenance of neurological 
status, and the radiographic determination of appropriate 
lesion safety margin in each treated vertebral body.
Results
Patient demographics
Two hundred and twenty-five patients were enrolled (147 
treatment and 78 sham); demographics and baseline 
characteristics were similar between groups (Table 1). Fol-
low-up was 98.7, 98.2, and 96.9% at 3, 6, and 12 months, 
respectively. Six patients exited the study: two patients with-
drew consent prior to evaluation at 3 months; three patients 
were terminated after choosing to undergo invasive surgi-
cal procedures on the spine; one patient died prior to the 
12 month visit for reasons not related to the study. See Fig. 2 
for study flow diagram by treatment arm. 
Treatment success
All patients were successfully treated except for one treat-
ment arm patient with extremely dense bone at S1. Targeting 
success was defined as overlap between the RF created abla-
tion zone and the terminus of the BVN at each level treated 
observed on 6 week MR imaging. Targeting was success-
ful in 129 of 145 patients (89.0%) or in 300 of 317 treated 
vertebral bodies (94.6%). Lack of targeting success at any 
one level removed the patient from the ITT group as both 
the cephalad and caudal vertebral body at an affected level 
were required to be successfully treated. Representative MR 
imaging of the lesion created to ablate the BVN at 6 weeks 
and 6 months is shown in Fig. 3.
Levels treated
Most commonly L5–S1 (122/224 patients) and L4–L5 
(45/224) followed by L4–L5–S1 (41/224) were treated. An 
additional nine patients were treated only at L3–L4 with 
seven patients treated at L3–L4–L5.
ODI
In the ITT population at 3 months, the treatment group 
exhibited a 19.0 least squares mean (LSM) improvement 
in ODI compared to a 15.4 LSM improvement in the sham 
group (p = 0.107). In the PP population at 3 months, the 
treatment group exhibited a 20.5 LSM improvement in ODI 
compared to a 15.2 LSM improvement in the sham group 
(p = 0.019). The primary outcome analysis is shown in 
Table 2.
Using a 10-point improvement in ODI, the commonly 
accepted minimum clinically important difference (MCID) 
in the treatment of CLBP [14, 15], 75.6% of treatment arm 
patients compared with 55.3% of sham arm patients exhib-
ited a successful response.
VAS
The LSM improvement in VAS in the treatment arm was 
2.97, 3.04, and 2.84 cm at 3, 6, and 12 months, respec-
tively. The LSM improvement in VAS in the sham arm was 
2.36, 2.08, and 2.08 cm at 3, 6, and 12 months, respectively 
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Table 1  Patient demographics 
and baseline characteristics
BDI Beck Depression Inventory, PCS physical component summary, MCS mental component summary
a p value from a two-way ANOVA with treatment group and analysis center as factors
b p value from a CMH general association test stratified by analysis center
c p value from a CMH row mean scores test stratified by analysis center
Characteristic Intracept system arm (n = 147) Sham control arm (n = 78) p
Age (years), mean (range) 46.9 (26–69) 47.1 (25–69) 0.869a
Male, n (%) 82 (55.8%) 41 (52.6%) 0.708b
BMI (kg/m2), mean (range) 27.44 (18.9–38.4) 27.16 (19.2–38.0) 0.666a
Caucasian, n (%) 134 (91.2%) 71 (91.0%) 0.409b
Married, n (%) 101 (68.7%) 50 (64.1%) 0.142b
College degree or higher, n (%) 87 (59.2%) 47 (60.3%) 0.535b
Working before procedure, n (%) 110 (74.8%) 57 (73.1%) 0.328b
Current tobacco use, n (%) 25 (17.0%) 10 (12.8%)
Duration low back symptoms, n (%)
 ≥ 6 months to < 1 year 6 (4.1%) 4 (5.1%) 0.990c
 ≥ 1 year to < 2 years 15 (10.2%) 8 (10.3%)
 ≥ 2 years to < 3 years 10 (6.8%) 5 (6.4%)
 ≥ 3 years to < 5 years 18 (12.2%) 7 (9.0%)
 ≥ 5 years 98 (66.7%) 54 (69.2%)
Opioid use before procedure, n (%) 51 (34.7%) 27 (34.6%) 0.872b
Modic changes, n (%)
 Type 1 46 (31.3%) 29 (37.2%) 0.578b
 Type 2 89 (60.5%) 42 (53.8%)
 Type 1 and Type 2 12 (8.2%) 7 (9.0%)
ODI mean (range) 42.9 (30–76) 41.1 (26–78) 0.277a
VAS mean (range) 6.82 (4.0–10.0) 6.63 (4.0–9.1) 0.343a
BDI mean (range) 7.7 (0–23) 7.6 (0–24) 0.853a
SF-36 PCS mean (range) 33.22 (14.83–48.11) 34.07 (14.01–54.15) 0.407a
SF-36 MCS mean (range) 51.97 (23.05–69.06) 52.72 (20.07–73.38) 0.579a
Fig. 2  Flow diagram of the 
study design
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(p = 0.083, 0.008, and 0.038). The MCID for VAS is 1.5 cm 
[14]. Table 3 summarizes the patient reported outcomes for 
ODI and VAS by follow-up interval and treatment arm; 
mean values are plotted in Fig. 4.
SF‑36, PCS and MCS
The LSM change in PCS in the PP treatment arm was 9.74, 
10.2, and 9.17 at 3, 6, and 12 months, respectively. The LSM 
change in PCS in the PP sham arm was 9.05, 8.73, and 7.63 
at 3, 6, and 12 months, respectively (N.S. all time periods). 
The MCID for the PCS has been reported as 4.9 [16].
The LSM change in MCS in the PP treatment arm was 
2.24, 1.90, and 1.13 at 3, 6, and 12 months, respectively. The 
LSM change in MCS in the PP sham arm was 0.78, 1.17, 
and − 1.46 at 3, 6, and 12 months, respectively (N.S. 3 and 
6 months; p = 0.021 at 12 months).
Cross‑over
Patients in the sham arm were offered active treatment at 
1 year post-op; 57 of 78 patients (73%) elected to cross-over. 
Only safety data up to 3 months were collected following 
the cross-over.
Adverse events
Adverse events (AEs) were continuously assessed during the 
study and reported as they occurred; there was no require-
ment that an event be associated with the study or study 
device. Each AE was assessed by the study investigator for 
severity and relationship to the study device or procedure. 
An independent review of clinical trial execution and safety 
data was performed on a regular basis by an external Data 
Safety Monitoring Board (DSMB) throughout the course 
of the trial.
There were no device- or procedure-related patient 
deaths, no unanticipated adverse device effects, and no 
device-related serious adverse events (SAEs). One device-
related AE occurred in a sham patient, who crossed over to 
the active treatment at 1 year. The patient was on hormone 
therapy and developed a VCF. Further diagnostic workup 
revealed concomitant osteopenia. By 8 weeks, the fracture 
was healed with no further complications.
Eight procedure-related events were reported in six 
patients following the 225 index procedures, for a compli-
cation rate of 2.7%. Two of these six patients were in the 
sham arm. The events included nerve root injury (n = 1), 
lumbar radiculopathy (n = 2), retroperitoneal hemorrhage 
(n = 1), and transient motor or sensory deficits (n = 4). The 
Fig. 3  MR imaging of patient treated and L4–L5–S1 as seen at 6 weeks (left image) and 6 months (right image). The lesion is roughly centered 
in the middle of the vertebral body; bone remodeling and healing is observed by 6 months
Table 2  Summary of ODI primary end point analyses
ITT population Intracept system arm (n = 147) Sham control arm (n = 78) p
 LS mean ODI change from baseline 95% confidence interval for LS mean − 19.0 [− 21.6, − 16.5] − 15.4 [− 18.9, − 11.9] 0.107
PP population Intracept system arm (n = 128) Sham control arm (n = 77) p
 LS mean ODI change from baseline 95% confidence interval for LS mean − 20.5 [− 23.2, − 17.8] − 15.2 [− 18.7, − 11.7] 0.019
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singular case of nerve root injury was in a sham patient, 
secondary to trocar misplacement during attempted dock-
ing at the pedicle. An excessively lateral position resulted 
in a psoas hematoma, and the resulting compressive lesion 
caused a transient neuropraxia on the femoral nerve. These 
events occurred during the perioperative period and the 
rate between arms was statistically compared using Fish-
er’s Exact test, which determined no significant difference 
between the arms (p = 1.000). All events resolved. There 
were no reports of aberrant burns, thermal nerve injuries, 
nor neurological injuries related to the delivery of RF energy 
within the vertebral body.
MRI evaluation at the 6-week and 6-month follow-up 
time points found no evidence of any spinal cord abnor-
malities, avascular necrosis or accelerated disc degeneration. 
Review of MR imaging at 6-week and 6-month follow-up 
revealed that a single patient had a change in Modic Type 
from 1 to 2 between the 6-week and 6-month time points 
at the inferior level of L5 and the superior level of S1. No 
patient developed Modic changes at an L3–S1 endplate 
by 6-month follow-up that was not present at the time of 
enrollment.
Discussion
The mechanisms and pathways on the origin of chronic 
low back pain associated with degenerative changes in the 
intervertebral disc have been studied for more than half a 
century. Unlike etiologies with a clear pathological cause, 
such as disc herniation, spondylolisthesis or spinal stenosis, 
CLBP appears to arise in part following disc and endplate 
degeneration with subsequent changes in the endplate mor-
phology and biology. Inflammatory mediators have been 
Table 3  Summary of ODI and 
VAS scores (PP population)
* p values from ANCOVA with factors of treatment group, analysis center and treatment group by analy-
sis center interaction, and a covariate of baseline ODI or VAS score
Follow-up period Variable Intracept 
system arm 
(n = 128)
Sham control arm (n = 77) p*
Mean (SD)
ODI
 Baseline ODI score 42.4 (10.92) 41.2 (10.38)
 3 months ODI score 22.1 (15.39) 25.8 (17.44) 0.019
ODI improvement from baseline − 20.3 (15.56) − 15.5 (17.87)
 6 months ODI score 21.6 (14.92) 25.1 (15.29) 0.078
ODI improvement from baseline − 20.8 (15.92) − 16.1 (16.38)
 12 months ODI score 22.6 (15.71) 25.3 (14.92) 0.153
ODI improvement from baseline − 19.8 (16.18) − 15.9 (16.20)
VAS
 Baseline VAS score 6.73 (1.38) 6.64 (1.34)
 3 months VAS score 3.80 (2.63) 4.14 (2.64) 0.083
VAS improvement from baseline − 2.90 (2.64) − 2.47 (2.49)
 6 months VAS score 3.74 (2.68) 4.41 (2.76) 0.008
VAS improvement from baseline − 2.98 (2.64) − 2.21 (2.45)
 12 months VAS score 3.96 (2.83) 4.46 (2.78) 0.038
VAS improvement from baseline − 2.76 (2.89) − 2.16 (2.69)
Fig. 4  Mean values of ODI and 
VAS plotted for all f/u times 
through 1 year. ODI improve-
ment in treatment arm statisti-
cally significant compared to 
sham arm at 3 months; VAS 
improvement statistically 
significant at 6 and 12 months 
(p < 0.05)
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shown to be expressed following disc injury, leading to a 
cascade of further inflammatory response via cytokine pro-
duction [17].
Direct evidence supporting the vertebral body as a source 
of clinical pain was provided by Kuslich et al. who reported 
on a series of patients during laminectomy using local anes-
thesia only. They reported that direct intraoperative mechan-
ical stimulation of the endplates of these awake patients con-
sistently provoked significant pain response [18]. Additional 
evidence for the endplate’s role in generation of pain signals 
was provided by Lotz et al., who performed a histomorpho-
logical study of human vertebral bodies which documented 
endplate nociceptor densification with increased disc degen-
eration [19].
Heggeness et al. observed that injection into the disc, 
as during discography, caused the endplates to deform and 
hypothesized that this deformation could account for the 
pain experienced during a discogram in some patients [20]. 
After hypothesizing that increased physical activity could 
instigate disc degeneration, Adams et al. showed that minor 
damage to the vertebral endplates could lead to structural 
changes in the adjacent intervertebral discs [21, 22]. Car-
ragee et al. determined that vertebral body and endplate 
MRI signal changes, indicative of intraosseous edema or 
inflammation, were well correlated with clinical low back 
pain [23].
Further correlation between vertebral body pathology 
and CLBP was described by Modic et al. who described 
intraosseus MRI changes adjacent to the vertebral end-
plates in patients with CLBP [24]. Weishaupt et al. reported 
100% specificity to pain in patients with Type 1 and Type 2 
Modic changes and furthermore observed strong and very 
similar positive predictive values and specificity associated 
with both Type 1 (88%) and Type 2 (96%) Modic changes 
[25]. Kuisma et al. found a 2.28 odds ratio for the presence 
of Modic changes at L5–S1 in patients with CLBP [26]. 
Although Rahme and Mossa found that low back pain is 
more commonly associated with Type I Modic changes, 
they also noted that this association was sometimes made 
based on relatively small sample sizes, and that other studies 
showed correlation between both Type 1 and Type 2 Modic 
changes and low back pain [27]. Schroeder et al. recently 
observed cytokine elevation in patients with Modic Type 2 
MR signals treated with anterior lumbar fusion, indicating 
that both Type 1 and Type 2 changes may be associated with 
low back pain [28].
In longitudinal studies, a change in Modic presentation 
from Type 1 to Type 2 has been observed, with the con-
comitant observation that pain was more likely associate 
with Type 1 presentation [24, 29]. In the present study, 
approximately 68% of patients reported experiencing low 
back pain for more than 5 years, suggesting that the higher 
baseline incidence of Modic Type 2 changes observed may 
reflect the transition of Modic Type 1 findings to Type 2 over 
time. Kjaer et al. have observed that Type 1 Modic changes 
are correlated with more recent low back pain, which may 
in part explain the higher prevalence of Type 2 findings in 
the SMART patient population who were symptomatic for 
over half a decade [30, 31]. Note that during the course of 
the SMART study itself, only a single instance of Type 1 to 
Type 2 conversion was observed. No statistical difference 
was observed in outcome between patients presenting with 
Type 1 versus Type 2 Modic changes.
The SMART trial was designed to test the hypothesis 
that the BVN plays an important role in the transmission of 
pain signals in patients with CLBP. The data showed that 
ablation of the BVN in the treatment arm decreased patients’ 
mean ODI by more than twice the MCID. The magnitude 
of the decrease was in line with decreases in ODI previ-
ously observed following fusion and total disc replacement 
(TDR) surgery. Two common TDRs, the Charité and the 
ProDisc, report an average percent improvement in ODI 
of 42.0% at 3 months, which compares favorably with the 
48.5% improvement at 3 months observed in the treatment 
arm of the present study [32, 33]. These TDR studies were 
controlled against fusion; the average percent improvement 
in ODI of the patients receiving fusion was 35.0%. However, 
the patients in these TDR studies were permitted to enroll 
with conditions other than just isolated back pain, including 
stenosis or disc herniation. Studies looking at strictly chronic 
low back patients report lower percentage improvements in 
ODI. For example, Fritzell et al. reported a 25% improve-
ment in ODI in their CLBP patients surgically treated with 
fusion, whereas Brox et al. reported a 37% improvement 
in ODI in fused CLBP patients [1, 34]. Thus, the improve-
ment in patient outcome observed in the treatment arm of the 
SMART study was comparable to that observed following 
TDR and fusion procedures for similar etiologies.
The mean improvement in ODI in the ITT sham arm 
was 15.4 points at 3 months, and was durable at 6 and 
12 months. Positive responses to placebo or sham treatments 
are well-recognized, especially in chronic pain populations, 
where the degree and duration of sham effectiveness often 
approaches that of active treatment [35–38]. Furthermore, 
multiple studies evaluating medical devices against sham 
interventions also suggest a correlation between the magni-
tude of the sham response and the invasiveness of the treat-
ment [39–45].
The cognitive perception of chronic pain is a function 
of peripheral nociceptor input and complex central neu-
robiological modulation. Historically, clinical placebo or 
sham effects were attributed to statistical and not biologi-
cal factors. Placebos were included in trials to statistically 
filter out the “noise” not associated with the mechanism of 
action of the proposed pharmacological or surgical treat-
ment itself. In such a model, the total treatment effect is 
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a linear superposition of the placebo effect and the inter-
ventional effect. A high placebo response in such a linear 
model is interpreted to indicate that the treatment effect is 
minimal and the procedure or drug is not particularly effec-
tive. However, newer models, particularly when studying 
pain, recognize that modulation of the central brain response 
through modification of expectations is an integral part of 
the patient’s response to any treatment. These models incor-
porate the sham response as part of the overall treatment 
effect, and have been developed to the point where they can 
distinguish which patients are going to have a higher central 
brain response (sham response) as opposed to peripheral 
response (intervention response).
Supporting this neurobiological basis for a placebo or 
sham response, Tétreault et al. performed an elegant study 
where they first confirmed brain activity associated with a 
placebo response, and then a priori predicted which patients 
in a subsequent study would show a placebo response [46]. 
The ability to predict, opposed to just document, a placebo 
response and to map areas of the brain associated with that 
response suggests that in a given population there exist 
a range of patient responses to a specific pain alleviation 
therapy, from almost pure central brain placebo response 
to nearly pure peripheral stimulatory inhibitory response. 
Treatments may act on one or the other response in varying 
degrees, but the documentation through randomized con-
trolled study of the ability to relieve both peripheral and 
central pain is important to the adoption of a new surgical 
therapy. The ability in the SMART trial to distinguish the 
active treatment from the sham treatment suggests that abla-
tion of the BVN has therapeutic value, although the overall 
pain response in a given patient is a complex function of the 
combined effects of placebo and treatment.
Radiofrequency ablation of the BVN for the relief of 
chronic low back pain represents a new treatment modality 
and is distinct from other RF ablation therapies used in the 
spine such as facet ablation. BVN ablation is technically and 
scientifically distinct from facet ablation because it uses a 
transpedicular approach into the vertebral body to access 
the BVN directly to alleviate vertebrogenic pain, and fur-
thermore mandates strict patient selection criteria. Note that 
facet ablation may have varying effectiveness as a function 
of patient selection, as recently reported by Juch et al. [47].
In the present study, using a 10-point ODI improvement 
as a threshold, 75.6% of treatment arm patients as opposed to 
55.3% of sham arm patients were characterized as respond-
ers. In addition, the treatment group reported statistically 
significant improved outcomes compared to the sham group. 
Comparison of the difference in outcome score between the 
sham and treatment groups does not represent the clinical 
utility of the Intracept Procedure because a sham treatment 
is not a clinically acceptable treatment for CLBP, nor is a 
sham response likely to occur in an open label setting. The 
overall therapeutic value of the procedure should be viewed 
through its safety profile and observed improvements from 
patient baseline, which are the same filters applied to other 
more invasive procedures which have not been compared to 
sham treatment. The results of this study support BVN abla-
tion as a minimally invasive treatment for relief of chronic 
low back pain.
Summary
We report on a multi-center, randomized, double-blind, 
sham-controlled trial conducted on a well-defined cohort 
of patients with chronic low back pain presenting with con-
comitant Modic changes at the diagnosed level. Patients in 
the per-protocol analysis treated using RF ablation of the 
BVN nerve complex exhibited statistically superior relief of 
disability and a higher response rate than those treated with 
the sham procedure.
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